These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 27771185

  • 1. Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
    Habets MN, van Selm S, van Opzeeland FJ, Simonetti E, Hermans PWM, de Jonge MI, Diavatopoulos DA.
    Vaccine; 2016 Nov 21; 34(48):5968-5974. PubMed ID: 27771185
    [Abstract] [Full Text] [Related]

  • 2. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media.
    Sabirov A, Metzger DW.
    Vaccine; 2006 Jul 07; 24(27-28):5584-92. PubMed ID: 16730398
    [Abstract] [Full Text] [Related]

  • 3. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
    Xu JH, Dai WJ, Chen B, Fan XY.
    Scand J Immunol; 2015 Mar 07; 81(3):177-85. PubMed ID: 25565478
    [Abstract] [Full Text] [Related]

  • 4. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
    Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, Briles DE, Kunisawa J, Inoue Y, Yamamoto M, Akiyoshi K, Kiyono H.
    Infect Immun; 2013 May 07; 81(5):1625-34. PubMed ID: 23460513
    [Abstract] [Full Text] [Related]

  • 5. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J, Aramaki Y.
    Int Immunopharmacol; 2018 Aug 07; 61():385-393. PubMed ID: 29945026
    [Abstract] [Full Text] [Related]

  • 6. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B, Chen X, Yu J, Zhang Y, Mo Z, Gu T, Kong W, Wu Y.
    Microb Pathog; 2018 Oct 07; 123():115-119. PubMed ID: 29959043
    [Abstract] [Full Text] [Related]

  • 7. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L, Liu Y, Wang H, Liao P, Song Z, Gao S, Wu Y, Zhang X, Yin Y, Xu W.
    Vaccine; 2015 Feb 18; 33(8):1008-16. PubMed ID: 25595867
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF, Ferreira DM, Moreno AT, Chavez-Olortegui C, Machado de Avila RA, Oliveira ML, Ho PL, Miyaji EN.
    Microb Pathog; 2012 Feb 18; 53(5-6):243-9. PubMed ID: 22981893
    [Abstract] [Full Text] [Related]

  • 9. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model.
    Xu Q, Pryharski K, Pichichero ME.
    Vaccine; 2017 Jan 05; 35(2):337-344. PubMed ID: 27919628
    [Abstract] [Full Text] [Related]

  • 10. Effect of a pneumococcal whole cell vaccine on influenza A-induced pneumococcal otitis media in infant mice.
    Manning J, Dunne EM, Wang N, Pedersen JS, Ogier JM, Burt RA, Mulholland EK, Robins-Browne RM, Malley R, Wijburg OL, Satzke C.
    Vaccine; 2019 Jun 06; 37(26):3495-3504. PubMed ID: 31103366
    [Abstract] [Full Text] [Related]

  • 11. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
    Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks-Walter A.
    Vaccine; 2000 Dec 08; 19 Suppl 1():S87-95. PubMed ID: 11163470
    [Abstract] [Full Text] [Related]

  • 12. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.
    Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW.
    Infect Immun; 2001 Nov 08; 69(11):6718-24. PubMed ID: 11598043
    [Abstract] [Full Text] [Related]

  • 13. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH.
    Vaccine; 2011 Aug 05; 29(34):5731-9. PubMed ID: 21696869
    [Abstract] [Full Text] [Related]

  • 14. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ.
    Infect Immun; 2012 Mar 05; 80(3):1166-80. PubMed ID: 22158740
    [Abstract] [Full Text] [Related]

  • 15. Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.
    Kuipers K, Jong WSP, van der Gaast-de Jongh CE, Houben D, van Opzeeland F, Simonetti E, van Selm S, de Groot R, Koenders MI, Azarian T, Pupo E, van der Ley P, Langereis JD, Zomer A, Luirink J, de Jonge MI.
    Infect Immun; 2017 Oct 05; 85(10):. PubMed ID: 28717032
    [Abstract] [Full Text] [Related]

  • 16. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X, Li B, Yu J, Zhang Y, Mo Z, Gu T, Kong W, Zhang Y, Wu Y.
    Med Microbiol Immunol; 2019 Apr 05; 208(2):215-226. PubMed ID: 30707297
    [Abstract] [Full Text] [Related]

  • 17. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
    Salcedo-Rivillas C, Debrie AS, Miyaji EN, Ferreira JM, Raw I, Locht C, Ho PL, Mielcarek N, Oliveira ML.
    Clin Vaccine Immunol; 2014 Jul 05; 21(7):972-81. PubMed ID: 24807055
    [Abstract] [Full Text] [Related]

  • 18. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).
    Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN.
    Microb Pathog; 2010 Jun 05; 48(6):205-13. PubMed ID: 20206678
    [Abstract] [Full Text] [Related]

  • 19. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
    Zhang Y, Guo X, Guo M, Chen X, Li B, Yu J, Gu T, Kong W, Wu Y.
    Immunol Res; 2019 Oct 05; 67(4-5):398-407. PubMed ID: 31773490
    [Abstract] [Full Text] [Related]

  • 20. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
    Lu J, Guo J, Wang D, Yu J, Gu T, Jiang C, Kong W, Wu Y.
    Hum Vaccin Immunother; 2019 Oct 05; 15(2):371-380. PubMed ID: 30235046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.